Oncologic 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: What All Physicians Need to Know - 20/03/18
, Rikesh J. Makanji, MD a, Bruce J. Barron, MD bAbstract |
Fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) hybrid examinations (PET/computed tomography, PET/magnetic resonance imaging) have become the most common PET imaging tools in the evaluation of the oncologic patient. Therefore it is of paramount importance that physicians who take care of oncology patients in any capacity are familiar with the basics of when these examinations are indicated, know how to best prepare the patients, and understand the benefits and limitations of the procedure. Additionally, it is important to understand which medical conditions and medications need to be controlled to maintain the diagnostic accuracy of these tests. In this article we aim to explain what 18F-FDG is, how to best prepare our patients, what PET is, and how these examinations are interpreted. Finally, we discuss some of the limitations of these examinations.
Le texte complet de cet article est disponible en PDF.Keywords : FDG, Oncologic Imaging, Patient Preparation, PET, PET/CT, PET Imaging
Plan
| Funding: None. |
|
| Conflict of Interest: None. |
|
| Authorship: All authors had access to the data, and all authors had a role in the writing of the manuscript. |
Vol 131 - N° 4
P. 357-364 - avril 2018 Retour au numéro
Article précédent
- Introduction to Neuroimaging
- Elizabeth George, Jeffrey P. Guenette, Thomas C. Lee
- Dietary Sodium Interventions to Prevent Hospitalization and Readmission in Adults with Congestive Heart Failure
- Wilbert S. Aronow, Tatyana A. Shamliyan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?